ACTIVE

DECAPHAR

Export PDF
Financial year 2025 · closed on 31/12/2025
Net result
82,6 k €
+34.9% YoY
Gross margin
300,9 k €
+2.2% YoY
Equity
316,3 k €
-66.2% YoY
Workforce
2,0 ETP
+53.8% YoY

What does DECAPHAR do?

DECAPHAR is a Private limited company incorporated in 2012. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Oudenaarde. It employs on average 2,0 ETP workers (FTE).

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0843.302.261
Incorporation
16/01/2012
Legal form
Private limited company
Registered office
Diependale 8
9700 Oudenaarde · FlandreSee on map
Contributed capital
286 327,00 €
Latest accounts
31/12/2025
Average workforce
2,0 ETP
Activities (NACE)
47730Dispensing chemist in specialised stores· main47730Dispensing chemist in specialised stores
Joint committees (4)
  • 100
  • 119
  • 201
  • 313
Signals
ProfitableLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 13 financial years

2025202420232022202120192018201720162015201420132012
Income statement
Gross margin300,9 k €294,5 k €327,2 k €288,4 k €298,1 k €448,4 k €610,1 k €437,5 k €556,5 k €487,5 k €569,7 k €174 k €310,1 k €
EBITDA186,2 k €150,8 k €160,1 k €143,7 k €193,7 k €172,9 k €181 k €51,6 k €168,8 k €119,1 k €218,7 k €-51 k €137 k €
Operating result108,9 k €73,3 k €83 k €65,1 k €81,9 k €-29,3 k €-18,9 k €-158,3 k €15,2 k €-539 €104,9 k €-174,5 k €28,6 k €
Net result82,6 k €61,2 k €83,5 k €65,7 k €83,1 k €-1,8 k €-66,9 k €-196,2 k €-58,7 k €-18,9 k €76,6 k €-200,8 k €22 k €
Balance sheet
Equity316,3 k €935,6 k €874,4 k €790,9 k €725,2 k €894,7 k €896,5 k €963,4 k €1,2 M €1,2 M €237,2 k €160,5 k €40,6 k €
Total assets1,6 M €2,3 M €1,5 M €1,6 M €1,6 M €2,1 M €1,7 M €2,1 M €2,3 M €2,2 M €1,3 M €1,6 M €940,8 k €
Cash410,3 k €431,3 k €255,9 k €280,5 k €206,4 k €179,2 k €313,4 k €359,5 k €851,7 k €1,2 M €223,3 k €248,2 k €52,7 k €
Debts1,3 M €1,3 M €655,8 k €829 k €886,6 k €1,2 M €769,3 k €1,1 M €1,1 M €977,2 k €1 M €1,5 M €900,2 k €
Other
Workforce2,0 ETP1,3 ETP2,4 ETP2,3 ETP2,0 ETP–6,0 ETP5,6 ETP5,0 ETP5,1 ETP5,0 ETP1,3 ETP3,1 ETP
Estimate

Indicative valuation

As an indication, this company is worth

between 250 k€ and 500 k€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2024 · 2 active · 6 ended

Active mandates

Conrad Pharma

Director · since 30 septembre 2024 · 0536.875.697

Represented by Vanessa Pluym

Active
Philippe Verzele

Director · since 30 septembre 2024

Active

Ended mandates

Charlotte Declerck

Director · since 01 avril 2012

Ended
Dominique Declerck

Director · since 16 janvier 2012

Ended
Karine Allegaert

Director · since 16 janvier 2012

Ended
Charlotte Declerck

Mandate

Ended
At this address

Other companies at this address

CompanyCBE no.
Conrad Pharma● Active
0536.875.697
GEVA PHARMA● Active
0427.597.576
VERZELE PHARMA● Active
0896.764.703
VERZELE PHARMA ZWALM● Active
0475.231.407
Annual accounts

Full financial information

202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date28/08/202608/08/202527/05/202431/05/202311/05/202231/05/2021
General meeting24/08/202607/08/202502/05/202403/05/202304/05/202205/05/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

14 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202524/08/202628/08/2026DutchPDF
Abridged model31/12/202407/08/202508/08/2025DutchPDF
Abridged model31/12/202302/05/202427/05/2024DutchPDF
Abridged model31/12/202203/05/202331/05/2023DutchPDF
Abridged model31/12/202104/05/202211/05/2022DutchPDF
Abridged model31/12/202005/05/202131/05/2021DutchPDF
Micro model31/12/201906/05/202004/06/2020DutchPDF
Abridged model31/12/201801/05/201910/02/2020DutchPDF
Abridged model31/12/201702/05/201817/07/2018DutchPDF
Abridged model31/12/201603/05/201725/08/2017DutchPDF
Abridged model31/12/201504/05/201622/06/2016DutchPDF
Abridged model31/12/201406/05/201511/06/2015DutchPDF
Abridged model31/12/201307/05/201427/08/2014DutchPDF
Abridged model31/12/201202/05/201308/08/2013DutchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 250 k€ and 500 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 2 active · 6 ended

Active mandates

Conrad Pharma

Director · since 30 septembre 2024 · 0536.875.697

Represented by Vanessa Pluym

Active
Philippe Verzele

Director · since 30 septembre 2024

Active

Ended mandates

Charlotte Declerck

Director · since 01 avril 2012

Ended
Dominique Declerck

Director · since 16 janvier 2012

Ended
Karine Allegaert

Director · since 16 janvier 2012

Ended
Charlotte Declerck

Mandate

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Mandates10/10/2024
    MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
    PDF
  • Restructuring02/09/2020
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring18/06/2020
    WIJZIGING RECHTSVORM - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Registered office24/01/2020
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Capital / shares29/02/2016
    KAPITAAL - AANDELEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Restructuring21/05/2014
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring09/01/2014
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Mandates26/06/2012
    ONTSLAGEN - BENOEMINGEN
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 202582,6 k €↑
  2. 2024
    Annual accounts 202461,2 k €↓
  3. 2023
    Annual accounts 202383,5 k €↑
  4. 2022
    Annual accounts 202265,7 k €↓
  5. 2021
    Annual accounts 202183,1 k €↑
  6. 2019
    Annual accounts 2019-1,8 k €↑
  7. 2018
    Annual accounts 2018-66,9 k €↑
  8. 2017
    Annual accounts 2017-196,2 k €↓
  9. 2016
    Annual accounts 2016-58,7 k €↓
  10. 2015
    Annual accounts 2015-18,9 k €↓
  11. 2014
    Annual accounts 201476,6 k €↑
  12. 2013
    Annual accounts 2013-200,8 k €↓
  13. 2012
    Annual accounts 201222 k €
  14. 16/01/2012
    IncorporationPrivate limited company